Recombinant virus vaccination against 'self' antigens using anchor- fixed immunogens

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2536-2540

  Irvine, Kari R ^a   Parkhurst, Maria R ^a   Shulman, Eliza P ^a   Tupesis, Janis P ^a   Custer, Mary ^a   Touloukian, Christopher E ^a   Robbins, Paul F ^a   Gómez Yafal, Alicia ^b   Greenhalgh, Patricia ^b   Sutmuller, Roger P M ^c   Offringa, Rienk ^c   Rosenberg, Steven A ^a   Restifo, Nicholas P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Therion Biologics Corporation   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; TUMOR ANTIGEN;

ANIMAL CELL; ARTICLE; CELL SPECIFICITY; CROSS REACTION; IMMUNE RESPONSE; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TARGET CELL; VACCINATION; VACCINIA VIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT;

ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNITY; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES; HLA-A ANTIGENS; IMMUNITY, CELLULAR; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; TRANSFECTION; VACCINIA VIRUS;

EID: 0033151609     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Hellstrom, I., and Hellstrom, K. E. Tumor vaccines - a reality at last? J. Immunother., 21: 119-126, 1998.
2. Mitchell, M. S. Immunotherapy of melanoma. J. Investig. Dermatol. Symp. Proc., 1: 215-218, 1996.
3. Fenton, R. G., and Longo, D. L. Danger versus tolerance: paradigms for future studies of tumor-specific cytotoxic T lymphocytes. J. Natl. Cancer Inst., 89: 272-275, 1997.
4. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
5. Rosenberg, S. A., Zhai, Y., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Seipp, C. A., Einhorn, J. H., Roberts, B., and White, D. E. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst., 90: 1894-1900, 1998.
6. Irvine, K. R., Chamberlain, R. S., Shulman, E. P., Surman, D. R., Rosenberg, S. A., and Restifo, N. P. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. J. Natl. Cancer Inst., 89: 1595-1601, 1997.
7. Benichou, G., Takizawa, P. A., Ho, P. T., Killion, C. C., Olson, C. A., McMillan, M., and Sercarz, E. E. Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides. J. Exp. Med., 172: 1341-1346, 1990.
8. Deng, Y., Yewdell, J. W., Eisenlohr, L. C., and Bennink, J. R. MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I-restricted peptides recognized by antiviral CTL. J. Immunol., 158: 1507-1515, 1997.
9. Berzofsky, J. A. Designing peptide vaccines to broaden recognition and enhance potency. Ann. NY. Acad. Sci., 754: 161-168, 1995.
10. Kawakami, Y., Eliyahu, S., Delgado, C. H., Robbins, P. F., Sakaguchi, K., Appella, E., Yannelli, J. R., Adema, G. J., Miki, T., and Rosenberg, S. A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA, 91: 6458-6462, 1994.
11. Bakker, A. B., Schreurs, M. W., de Boer, A. J., Kawakami, Y., Rosenberg, S. A., Adema, G. J., and Figdor. C. G. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J. Exp. Med., 179: 1005-1009, 1994.
12. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
13. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A., and Chesnut, R. W. Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med., 173: 1007-1015, 1991.
14. Mazzara, G. P., Destree, A., and Mahr, A. Generation and analysis of vaccinia virus recombinants. Methods Enzymol., 217: 557-581, 1993.
15. Glitz, L., Destree, A., Cormier, N., Day, E., Stallard, V., Caiazzo, T., Mazzara, G., and Panicali, D. Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env. J. Virol., 64: 5948-5957, 1990.
16. Jenkins, S., Gritz, L., Fedor, C. H., O'Neill, E. M., Cohen, L. K., and Panicali, D. L. Formation of lentivirus particles by mammalian cells infected with recombinant fowlpox virus. AIDS Res. Hum. Retroviruses, 7: 991-998, 1991.
17. Restifo, N. P., Bacik, I., Irvine, K. R., Yewdell, J. W., McCabe, B. J., Anderson, R. W., Eisenlohr, L. C., Rosenberg, S. A., and Bennink, J. R. Antigen processing in vivo and the elicitation of primary CTL responses. J. Immunol., 154: 4414-4422, 1995.
18. Overwijk, W. W., Tsung, A., Irvine, K. R., Parkhurst, M. R., Goletz, T. J., Tsung, K., Carroll, M. W., Liu, C., Moss, B., Rosenberg, S. A., and Restifo, N. P. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med., 188: 277-286, 1998.
19. Zhai, Y., Yang, J. C., Spiess, P., Nishimura, M. I., Overwijk, W. W., Roberts, B., Restifo, N. P., and Rosenberg, S. A. Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MARTI and gp100. J. Immunother., 20: 15-25, 1997.
20. Anton, L. C., Yewdell, J. W., and Bennink, J. R. MHC class 1-associated peptides produced from endogenous gene products with vastly different efficiencies. J. Immunol., 158: 2535-2542, 1997.
21. Cerundolo, V., Elliott, T., Elvin, J., Bastin, J., Rammensee, H.-G., and Townsend, A. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. Eur. J. Immunol., 21: 2069-2075, 1991.
22. Dyall, R., Bowne, W. B., Weber, L. W., LeMaoult, J., Szabo, P., Moroi, Y., Piskun, G., Lewis, J. J., Houghton, A. N., and Nikolić-Žugić, J. N. Heteroclitic immunization induces tumor immunity. J. Exp. Med., 188: 1553-1561, 1998.
23. Hemmer, B., Vergelli, M., Pinilla, C., Houghten, R., and Martin, R. Probing degeneracy in T-cell recognition using peptide combinatorial libraries. Immunol. Today, 19: 163-168, 1998.